When two colorectal cancer cell lines were depleted of RECQL5, CPT sensitivity was remarkedly increased as compared to parental lines containing RECQL5. Additionally, CPTs successfully treated xenograft tumors derived from one of the RECQL5-deficient neoplastic cell lines though not cells consisting of RECQL5. This data suggested that RECQL5 likely contributes to CPT resistance in colorectal carcinoma and may be used as directed targeted therapy to treat colorectal malignant disease (Wang et al., 2011b). Here, RECQL5 is linked to colorectal carcinoma.